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A B S T R A C T   
Background: Despite its widespread use, computed tomography (CT) is not perfect for evaluating peritoneal 
metastases of colorectal origin before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy 
(CRS þ HIPEC). We therefore evaluated the value of adding diagnostic laparoscopy to CT when assessing patient 
eligibility for CRS þ HIPEC. 
Methods: This was a retrospective study of a consecutive series of 112 patients evaluated systematically by 
diagnostic laparoscopy and CT between January 2012 and January 2018. Patient eligibility for CRS þ HIPEC was 
assessed by the peritoneal cancer index (PCI) both at the time of initial diagnostic laparoscopy and during the 
retrospective review of CT images. Two experienced radiologists who were blinded to the PCI result at lapa-
roscopy then independently estimated the PCI based on CT imaging. The primary outcome was the number of 
patients eligible for CRS þ HIPEC by each method. 
Results: We identified 112 patients, of whom 95 (85%) were eligible for CRS þ HIPEC based on diagnostic 
laparoscopy and 84 underwent CRS þ HIPEC. Overall, 14 patients (17%) experienced an “open-and-close” 
procedure. In contrast to diagnostic laparoscopy, 100 patients (89%) were identified as being eligible for CRS þ
HIPEC by CT (p ¼ 0.13), which would have resulted in an additional five open-and-close procedures. 
Conclusions: Adding diagnostic laparoscopy to CT produced a clinically relevant, but statistically non-significant, 
reduction in the number of patients eligible for CRS þ HIPEC. We conclude that diagnostic laparoscopy may be of 
use in preoperative assessments when systematic analysis by CT scores the PCI as greater than ten. Future 
research should focus on the cost-effectiveness of this approach.   
1. Introduction 
Cytoreductive surgery plus hyperthermic intraperitoneal chemo-
therapy (CRS þHIPEC), which was first implemented in the early 1990s, 
is a curative treatment for patients with low-volume peritoneal metas-
tases without other distant metastases [1]. Before its introduction, there 
was no viable cure for patients with peritoneal metastases of colorectal 
origin. The five-year survival after treatment with CRS þ HIPEC now 
varies between 41% and 45% [2,3]. 
Computed tomography (CT) is typically considered the diagnostic 
standard for determining whether patients with peritoneal metastases of 
colorectal origin are eligible for CRS þHIPEC [4]. Peritoneal metastases 
can be quantified on CT by the peritoneal cancer index (PCI), which 
scores the tumor load in the abdomen and has been shown to predict 
survival reliably [5–7]. However, CT has a wide sensitivity range of 
24.5%–79% for detecting peritoneal metastases, potentially under-
estimating the PCI by 24%–33% [4,8–12]. Although patients with very 
low PCIs are ideal candidates for CRS þ HIPEC, small peritoneal lesions 
are difficult to detect by CT [13–15]. Furthermore, if tumor loads are 
found to be excessive at operation, underestimation can lead to 
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unnecessary “open-and-close” procedures and avoidably prolonged re-
covery times and complications. Accurate patient identification can 
therefore ensure optimal use of surgical and financial resources. To 
correct for this, it has been proposed that PCI estimation before CRS þ
HIPEC be performed by CT and diagnostic laparoscopy. Indeed, the 
latter has proven feasibility and safety, with the potential to prevent 
28%–55% of unnecessary laparotomies [16–20]. To date, however, no 
study has compared CT- and laparoscopy-based PCI, leaving uncertainty 
as to whether the addition of diagnostic laparoscopy to CT could prevent 
more open-and-close procedures than CT alone. 
In this study, our aim was to evaluate whether diagnostic laparos-
copy should be added to CT when selecting patients for CRS þ HIPEC. 
We hypothesized that fewer patients would be declared eligible for CRS 
þ HIPEC when using diagnostic laparoscopy than when using CT. 
2. Materials and methods 
2.1. Study design 
This was a single-center retrospective study performed at the Uni-
versity Medical Center Groningen, which is a tertiary referral center for 
a region with 3.5 million inhabitants. The hospital accepts referrals for 
patients with peritoneal metastases who could be suitable for treatment 
by CRS þ HIPEC. Since 2012, we have used diagnostic laparoscopy as a 
standard procedure to select patients for CRS þ HIPEC. The number of 
peritoneal metastases was quantified systematically by estimating the 
PCI at diagnostic laparoscopy (Fig. 1) [21]. A PCI exceeding 20 was 
again taken as a cut-off point, above which CRS þ HIPEC was not per-
formed. In general, patients are considered ineligible for CRS þ HIPEC 
when the PCI exceeds 20, they show extra-abdominal metastases other 
than resectable liver metastases or if they are not fit enough for surgery. 
CT scan was used to detect extra-abdominal metastases rather than 
peritoneal metastases. Therefore there was no systematic scoring of the 
PCI following the PCI score form during our daily clinical practice. 
During the study period, diagnostic laparoscopy was not performed in 
patients that clearly showed irresectable disease during the initial 
CT-evaluation, which did not include the PCI score form. These patients 
could therefore not be included in this study. 
In this research, we included all consecutive patients with peritoneal 
metastases due to colorectal cancer who were seen between January 
2012 and January 2018, excluding patients with other synchronous 
malignancies of non-colorectal origin. The study was approved by the 
Central Ethical Committee of the University Medical Center Groningen. 
2.2. Data collection 
The PCI scores determined during diagnostic laparoscopy were 
extracted from the patients’ files. We also collected data on the following 
characteristics: age, gender, body mass index, comorbidities, tumor 
location, previous surgery, conversion of laparoscopy to laparotomy, 
and complications within 30 days of laparoscopy. Next, the PCIs from CT 
scans were obtained based on retrospective reviews by two radiologists 
with eight- and five-years’ experience in reading abdominal CT scans. 
All images were independently analyzed in coronal and transverse 
views, without knowledge of the laparoscopic PCI result, using a picture 
archiving and communication system (Carestream Health, Rochester, 
NY). In case of discrepancies in the PCI, consensus was reached through 
discussion between the radiologists. 
2.3. Endpoints 
The primary endpoint was the number of patients deemed eligible for 
CRS þ HIPEC according to either diagnostic laparoscopy or CT. The 
secondary endpoint was the difference in PCI estimation overall and in 
different intra-abdominal regions of the PCI (upper, central, and lower 
abdomen, plus the small intestines; Fig. 1). Other outcomes of interest 
were as follows: agreement between the diagnostic laparoscopy and the 
CT results, the number of conversions to laparotomy, the complications 
of diagnostic laparoscopy by 30 days post-surgery according to Clav-
ien–Dindo classification [22], and the interrater reliability between the 
two radiologists. The latter was used as a measure of quality. 
2.4. Statistical analysis 
Patient characteristics are reported using descriptive statistics. The 
McNemar test was used to compare the number of patients that would 
have been found eligible for CRS þ HIPEC by CT and diagnostic lapa-
roscopy. To evaluate whether the differences in the overall PCI between 
CT and diagnostic laparoscopy were comparable, the nonparametric 
Wilcoxon signed-rank test was used. A Bland–Altman plot was used to 
visualize differences between the overall PCI estimated by CT and that 
reported by diagnostic laparoscopy. The interrater reliability between 
the two radiologists was determined by the intraclass correlation coef-
ficient (ICC). Interpretation of the ICC was as follows: <0.0 ¼ poor; 
0.0–0.2 ¼ slight; 0.21–0.4 ¼ fair; 0.41–0.6 ¼ moderate; 0.61–0.8 ¼
substantial; and 0.81–1 ¼ almost perfect) [23]. We used IBM SPSS, 
Version 23.0 (IBM Corp., Armonk, NY, USA), to conduct all analyses. 
Fig. 1. Sugarbaker’s peritoneal cancer index. Tumor 
load is identified by nine abdominal regions and four 
small intestinal regions. The largest tumor lesion in 
each region is measured and rated as 0 (no tumor 
load) to 3 (lesion size >5 cm) points. Note: upper 
abdomen ¼ regions 1, 2, and 3; central abdomen ¼
regions 0, 4, and 8; lower abdomen ¼ regions 5, 6, 
and 7; and small intestines ¼ regions 9, 10, 11, and 
12. Abbreviations: LS ¼ lesion size score. Previously 
published as Jacquet P & Sugarbaker PH. Clinical 
research methodologies in diagnosis and staging of pa-
tients with peritoneal carcinomatosis. Cancer Treatment 
and Research 1996 [21]. Permission for usage was 
granted.   
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3. Results 
3.1. Patient characteristics 
In total, 112 consecutive patients were included in the study. 
Excluded were 2 patients with other synchronous malignancies, as they 
would not have been suitable for CRS þ HIPEC due to that malignancy. 
The baseline characteristics of the included patients are shown in 
Table 1. Most had a primary tumor in the colon (90%) and had under-
gone previous abdominal surgery (80%), such as hemicolectomy, sig-
moid resection, or appendectomy. In our center patients receive upfront 
CRS þ HIPEC. However, eight patients of this cohort received neo-
adjuvant chemotherapy, seven as part of another study [24] and one to 
downstage synchronous liver metastases. Although 95 patients (88%) 
were eligible for CRS þ HIPEC based on diagnostic laparoscopy, only 84 
underwent a laparotomy because 11 withdrew their consent for CRS þ
HIPEC after the diagnostic laparoscopy. After laparoscopy patients were 
better informed about how extensive CRS will be and their prognosis 
afterwards. Some patients therefore decided to not undergo CRS þ
HIPEC. Of these 84 patients, 14 (17%) underwent an open-and-close 
procedure. Reasons for open-and close procedures are listed in 
Table 3. Median time between diagnostic laparoscopy and laparotomy 
was 41 days (4–323) in all patients. For patients that experienced an 
open- and-close procedure median time between diagnostic laparoscopy 
and laparotomy was also 41 days (4–176). A flow-chart of the eligibility 
of patients for CRS þ HIPEC can be found in Fig. 2. 
3.2. PCI scores 
A PCI estimate from diagnostic laparoscopy was available for 108 
patients (96%). Estimation was impossible in three cases due to the 
presence of extensive adhesions and in one case due to a tumor limiting 
visualization. During diagnostic laparoscopy, 13 patients (12%) had a 
PCI score above 20 and were therefore ineligible for HIPEC. Although a 
PCI estimate was possible by CT scan for all patients, two CT scans were 
difficult to interpret due to motion artifacts and one CT scan had a 
limited view (only a part of the diaphragm was shown). The ICC be-
tween the two radiologists for the overall PCI score was substantial at 
0.74 (95% confidence interval 0.63–0.81). Of note, there was no sta-
tistically significant difference between the overall estimated PCI by 
diagnostic laparoscopy (median PCI, 5) and that by CT (median PCI, 6) 
(p ¼ 0.88; Table 2). The differences in PCI estimates between diagnostic 
laparoscopy and CT were independent of the average PCI (Fig. 3). 
3.3. Differences in eligibility for CRS þ HIPEC 
There was no statistically significant difference between the numbers 
of patients found to be eligible for CRS þ HIPEC by diagnostic lapa-
roscopy (95/112; 84.8%) and by CT (100/112; 89.3%) (p ¼ 0.125). All, 
but one, patient who were found ineligible for CRS þ HIPEC by CT scan 
were also found ineligible by diagnostic laparoscopy. From the 112 
included patients 95 were found eligible for CRS þ HIPEC, this means 
that 7 diagnostic laparoscopies were necessary to prevent one open-and- 
close procedure. Without the addition of diagnostic laparoscopy, 5 
additional patients (4.6%) who were unsuitable for CRS þ HIPEC might 
Table 1 
Characteristics of patients diagnosed with peritoneal metastases.  
Characteristic N ¼ 112 
Age 65 (28–77) 
Gender, N (%) 
Male 57 (50.9) 
Female 55 (49.1) 
Body mass index (kg/m2) 26.6 (19.0–40.4) 
Charlson comorbidity index 8 (6–11) 
Primary tumor, N (%) 
Colon 101 (90.2) 
Rectum 11 (9.8) 
Previous abdominal surgery, N (%) 
Yes 89 (79.5) 
No 23 (20.5) 
Neoadjuvant chemotherapy, N (%) 8 (7.1) 
Patients eligible for HIPEC after diagnostic laparoscopy, N (%) 95 (88) 
Patients scheduled for HIPEC, N (%) 84 (88) 
Open-and-close procedure, N (%) 14 (17%) 
Data are presented as medians (range), unless specified otherwise. 
Abbreviations: HIPEC ¼ hyperthermic intraperitoneal chemotherapy. 
Fig. 2. Flowchart of patients eligibility.  
Table 2 







PCI estimation possible, N 
(%) 
108 (96.4) 112 (100) .125* 
Patients eligible for HIPEC, 
N (%) 
95 (88.0) 100 (92.6) .125* 
PCI overall 5 (2; 11.75) 6 (2; 12) .882 
PCI upper abdomen 0 (0; 3) 0 (0; 3) .081 
PCI central abdomen 1 (0; 3) 2 (0; 5) <.001 
PCI lower abdomen 2 (0; 3) 2 (0; 4) .559 
PCI small intestine 0 (0; 1) 0 (0; 0) .036** 
Conversions, N (%) 20 (17.7)   
Complications, N (%) 
Clavien–Dindo class 1 4 (3.6)   
Clavien–Dindo class 2 2 (1.8)   
Data are presented as medians (25th percentile; 75th percentile) and were 
analyzed using the Wilcoxon signed-rank test, unless otherwise specified. * 
McNemar test was used. ** Despite the comparable medians, the significant 
difference between the PCI estimated by each method is seen in the different 
data distributions (note the 75th percentile). Abbreviations: HIPEC ¼ hyper-
thermic intraperitoneal chemotherapy; PCI ¼ peritoneal cancer index. 
Table 3 
Reasons for open-and-close procedures.  
Reason for open-and-close procedure N (%) ¼ 14 (100) 
PCI >20 6 (42.9) 
Tumor irresectabilty 5 (35.7) 
Extensive small bowel involvement 1 (7.1) 
Irresectable liver metastasis 1 (7.1) 
No PM 1 (7.1)  
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have undergone an open-and-close procedure. All 5 of these patients had 
a PCI score between 12 and 15 on their CT scan. 
4. Discussion 
We showed that adding diagnostic laparoscopy to CT produced a 
statistically non-significant reduction in the number of patients eligible 
for CRS þHIPEC, but that this approach was associated with fewer open- 
and-close procedures. However, failure to show a statistically significant 
difference in the PCI estimation by CT or diagnostic laparoscopy con-
flicts with our hypothesis that diagnostic laparoscopy would have a 
higher sensitivity than that of CT for detecting peritoneal metastases. 
To date, we could find no studies comparing diagnostic laparoscopy 
with CT in patient selection for CRS þ HIPEC based on the estimated 
PCI. Although some studies have been performed comparing the accu-
racies of CT and laparotomy [4,10–12], these showed that the median 
PCI score estimated by CT (7–26) was significantly lower than that 
estimated by laparotomy (13–39) (p-value, <0.001 to 0.003) [4,10–12]. 
One study illustrated that, despite CT scans underestimating the PCI, 
only 12% of patients would require an open-and-close procedure [4]. 
The unexpected high accuracy of CT scans in our study might reflect 
improvements in the quality of CT scans since those data were pub-
lished. Other explanations are that the radiologists were very experi-
enced in this subject matter and that they used a systematic method to 
estimate the PCI. 
Our results showed that significantly more peritoneal lesions in the 
small abdomen were detected by diagnostic laparoscopy than by CT 
scan. These results seem to be consistent with other research showing 
that CT has a low sensitivity for detecting peritoneal metastases of the 
small intestines, with rates ranging from 8% to 25% [10,11]. This is an 
important finding because small intestine involvement is a factor that 
limits tumor resectability. If extensive removal of the small intestines is 
required, patients can be left with functional problems, such as the 
short-bowel syndrome, after surgery. If CT is used in isolation for 
diagnosis before CRS þ HIPEC, the potential for open-and-close pro-
cedures may be increased for patients with nonresectable involvement 
of the small intestine. 
Our results showed that there was a non-significant reduction in the 
rate of open-and-close procedures based on adding diagnostic laparos-
copy to the preoperative workup. However, 17% of patients were still 
ineligible for CRS þHIPEC at the time of laparotomy. This is comparable 
to data in the literature, where the incidence of open-and-close pro-
cedures after diagnostic laparoscopy is reportedly 13%–38% [17–20,25, 
26]. This high residual incidence might be explained by the inability to 
evaluate all regions of the peritoneal cavity evenly in the presence of 
adhesions or tumor processes. This makes it questionable if diagnostic 
laparoscopy is the ideal diagnostic measurement. However, at this 
moment, this is the best diagnostic tool available, that does not include 
high risks for the patient. Furthermore, tumor progression might occur 
during the waiting time before CRS þ HIPEC. Although waiting time 
between DLS and laparotomy in patients that experienced an 
open-and-close procedure was comparable to that of patients that un-
derwent CRS þHIPEC, tumor progression may be faster in some patients 
than in others. In addition, diagnostic laparoscopy might introduce the 
risk of port-site metastases, but this has not been observed in any of our 
patients. 
We could identify no other research comparing diagnostic laparos-
copy with CT as a tool to facilitate patient selection for CRS þ HIPEC in 
cases of colorectal cancer. The experience of our radiologists preclude 
extrapolating the study results to other medical centers, where there 
should be awareness of the need for an adequate learning curve. A 
limitation of this study is its retrospective design, meaning that the ra-
diologists already knew that patients had peritoneal metastases and 
were participating in a study. Although this may have increased the 
detection rate of peritoneal metastases, we are convinced that it is 
consistent with the ability of experienced radiologists to determine the 
PCI using a systematic methodology. For example, radiologists in our 
tertiary referral center often re-evaluate CT scans from other hospitals, 
knowing that the patients are being evaluated for their suitability for 
CRS þ HIPEC. Consequently, the research approach strongly resembled 
clinical practice. The substantial intraclass correlation in this study also 
confirms that the estimation of the PCI by CT is reliable when done by an 
Fig. 3. Bland–Altman Plot of the differences in the overall PCI by CT and diagnostic laparoscopy. 
Abbreviations: CT ¼ computed tomography; PCI ¼ peritoneal cancer index. 
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experienced radiologist and that it can serve as a quality measure for 
inter-observer reliability. Another limitation is the small number of 
included patients, which might be the reason that the differences 
described in this study did not reach statistical significance. 
Although we found no significant difference in the number of pa-
tients eligible for CRS þHIPEC between the two diagnostic methods, the 
inclusion of diagnostic laparoscopy in the preoperative workup did most 
likely prevent five patients from undergoing avoidable open-and-close 
procedures assuming they would have all consented to CRS þ HIPEC. 
To avoid one open-and-close procedure it is necessary to perform seven 
diagnostic laparoscopies, which seem justified as a diagnostic laparos-
copy is known to be associated with both a short recovery time and a low 
risk of complications [17–19]. By contrast, open-and-close procedures 
place significant burdens on the patient and on hospital resources, which 
is important where health care rationing is a reality. By adding diag-
nostic laparoscopy to CT, these patients avoided unnecessary risks 
during their final phase of life. In case a HIPEC procedure is deemed 
impossible, patients can only be treated with palliative chemotherapy. 
After a laparotomy, however, time is required for recovery and, there-
fore possibly delaying the start of palliative chemotherapy. Had the 
procedures been performed, they would also have led to the loss of five 
full days in surgery and would have required 35 days of extra inpatient 
care. Although diagnostic laparoscopy also requires resources, the pro-
cedure normally takes 1 h to perform and patients will normally stay in 
hospital for one to three days. We must also consider that, in this study, 
20 cases required conversion to laparotomy, requiring a total time of 
two to 3 h in surgery. The main reason for these conversions were ad-
hesions making it impossible to determine the PCI. This also illustrates 
the drawback of a diagnostic laparoscopy. However, we are still 
convinced that even a conversion to a diagnostic laparotomy is less 
invasive as an open-and-close procedure as this often results in only an 
upper or lower midline incision in contrast to an incision from xiphoid to 
pubic symphysis. Finally, given that a CT scan is part of the standard 
workup of a patient with peritoneal metastases (to rule out distant 
metastases), this approach requires no additional resources. 
In the present research, all patients who would have experienced an 
open-and-close procedure without diagnostic laparoscopy had a PCI that 
exceeded ten. Therefore, when considering the optimal use of hospital 
resources and the costs and benefits for patients, it might be reasonable 
to use CT scans as the first-line tool for PCI estimation. Only in cases 
where the CT-based PCI exceeds ten do we recommend adding diag-
nostic laparoscopy to the preoperative workup. Furthermore, when the 
origin of the peritoneal metastases is unclear, a biopsy taken during 
laparoscopy provides an opportunity to add histological information. 
When CT is applied in a structured way to estimate the number of 
peritoneal metastases, it achieves comparable sensitivity to that of 
diagnostic laparoscopy. To further improve sensitivity, (diffusion 
weighted) magnetic resonance imaging (MRI) might prove useful for PCI 
estimation. Initial results with this approach have shown promise, with 
several studies describing higher accuracies for PCI estimation by MRI 
(82.1%–88%) than by CT (63%) [27–30]. However, MRI is not widely 
used in preoperative staging for several reasons. First, it is more time 
consuming than CT, making it unsuitable for many institutions. That 
said, MRI evaluation would take approximately 1 h, effectively requiring 
less time than a diagnostic laparoscopy. Second, its long scanning time 
and large field of view can lead to artifacts. Third, some patient groups 
are unable to undergo MRI, such as those with non-compatible pace-
makers or severe claustrophobia. In the future, a prospective study 
should be conducted to evaluate the accuracy of MRI versus diagnostic 
laparoscopy. This should follow a pre-determined protocol in which 
estimates for each method are made by independent evaluators. 
Cost-effectiveness analyses should also be central to any such study 
given that MRI is an expensive imaging modality. 
5. Conclusion 
We conclude that adding diagnostic laparoscopy to CT during pre-
operative staging leads to a clinically relevant, but a statistically non- 
significant, reduction in the rate of open-and-close procedures among 
patients with peritoneal carcinomatosis. Diagnostic laparoscopy can be 
added to preoperative staging when the PCI of a systematically reviewed 
CT scan exceeds ten. 
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